New pill ACT500 targets dual liver disease in early trial
NCT ID NCT07589400
First seen May 19, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This early-stage trial tests a new drug called ACT500 in 24 adults who have both fatty liver disease and chronic hepatitis B. The study is mainly checking if the drug is safe and how the body processes it. Participants will take ACT500 or a placebo pill once daily for a set period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
Contact
-
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACT500 tablets
What this could lead to
If successful, this could point toward a new treatment option for people with both fatty liver disease and chronic hepatitis B.
What could go wrong
This is a very early Phase 1 trial with only 24 people, so it is primarily checking safety and dosing. It is too soon to know if ACT500 will actually help the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.